What Is the evidence from past National Institute of Health and Care Excellence single-technology appraisals regarding company submissions with base-case incremental cost-effectiveness ratios of less than £10,000/QALY? by Carroll, C. et al.
This is a repository copy of What Is the evidence from past National Institute of Health and
Care Excellence single-technology appraisals regarding company submissions with 
base-case incremental cost-effectiveness ratios of less than £10,000/QALY?.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/123368/
Version: Accepted Version
Article:
Carroll, C. orcid.org/0000-0002-6361-6182, Houten, R., Boland, A. et al. (2 more authors) 
(2017) What Is the evidence from past National Institute of Health and Care Excellence 
single-technology appraisals regarding company submissions with base-case incremental 
cost-effectiveness ratios of less than £10,000/QALY? Value in Health. ISSN 1098-3015 
https://doi.org/10.1016/j.jval.2017.09.006
Article available under the terms of the CC-BY-NC-ND licence 
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
 
Title:  
What is the evidence from past National Institute of Health and Care Excellence (NICE) Single Technology 
Appraisals (STAs) regarding company submissions with base-case ICERs of less than £10,000 per QALY? 
 
Authors:  
Christopher Carroll, PhD, University of Sheffield 
Rachel Houten, MSc, University of Liverpool 
Angela Boland, PhD, University of Liverpool 
Eva Kaltenthaler, PhD, University of Sheffield 
Rumona Dickson, PhD, University of Liverpool 
 
Corresponding author: 
Christopher Carroll 
Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), 
University of Sheffield, Regent Court, Regent Street, Sheffield, S1 4DA 
Email: c.carroll@shef.ac.uk 
Tel: +44 (0)114 22 20864 
Fax: +44 (0)114 22 20749 
 
Financial Support: 
This project received no financial support. 
 
 
2 
 
Keywords: 
National Institute for Health and Care Excellence (NICE); Single Technology Appraisals (STA); Health policy; 
Base-case ICERs 
 
Running title: 
Criteria for minimal appraisal by NICE  
 
Acknowledgements: 
None 
 
 
 
Words: 4087 
 
 
 
 
 
 
 
 
 
3 
 
Abstract 
Objectives: 
The National Institute for Health and Care Excellence (NICE) has recently proposed that company submissions 
with a base-case ,&(5RIOHVVWKDQSHU4$/<PLJKWEHHOLJLEOHIRUDµIDVWWUDFN¶DSSUDLVDO7KH
objective of this study was to explore outcomes relating to previously-conducted STAs with base-case ICERs of 
less than £10,000 per QALY. 
Methods: 
All STAs with published guidance from 2009 to 2016 were included; those with company base-case ICERs of 
less than £10,000 per QALY were identified and analysed. A secondary analysis was also conducted for those 
with a company base-case ICER of £10,000-£15,000 per QALY. Relevant data were extracted and presented in 
a narrative and tables.  
Results: 
In total, 15% (26/171) of STAs included a company submission with a base-case ICER of less than £10,000 per 
QALY.  Of these, 73% (19/26) were given positive recommendations after the first Appraisal Committee (AC), 
while 27% (7/26) were initially given a Minded No before receiving a positive recommendation in the Final 
Appraisal Determination, albeit with restricted recommendations for three technologies. Five STAs had 
company base-case ICERs of £10,000-£15,000 per QALY and all received a positive recommendation after the 
first AC.  
Conclusions: 
The majority of previous STAs with a company base-case ICER of £10,000 or even £15,000 per QALY 
received a positive recommendation after the first AC, but a number proved more complicated and required 
detailed appraisal, which influenced the final recommendation. This finding might have implications for the 
SURSRVHG1,&(µIDVWWUDFN¶SURFHVV 
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Introduction 
The National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) process has 
been in existence since 2005. The process is undertaken for a technology for a single indication; it is outlined in 
detail in the Guide to the Single Technology Appraisal Process[1] and includes the production of a submission 
by the company that manufactures the technology. The FRPSDQ\¶V submission (CS) to NICE forms the principal 
source of evidence for decision making in the STA process. The CS is expected to contain an evaluation of the 
clinical effectiveness and cost-effectiveness of the technology using decision-analytic approaches outlined in the 
NICE Technology Appraisals Methods Guide[2]. The submission should also include an incremental cost 
effectiveness ratio (ICER), expressed as cost per Quality Adjusted Life-Year (QALY), as the measure of the 
WHFKQRORJ\¶VFRVW-effectiveness. An independent, academic Evidence Review Groups (ERG) is charged with the 
task of critically appraising the CS to identify strengths, weaknesses and gaps in the evidence presented. The 
ERG also undertakes exploratory analyses to explore uncertainties around the FRPSDQ\¶V model and resulting 
ICERs[3, 4]. The ERG report, together with the FRPSDQ\¶V submission, is considered by one of the four NICE 
Technology Appraisal Committees (ACs) in their deliberations. The findings of the committee are used to 
produce the Appraisal Consultation Document (ACD); after further considerations and a consultation period, a 
Final Appraisal Determination (FAD) is produced that results in NICE guidance. In some cases, only a FAD is 
produced, without the need for an ACD. WithiQWKHVHGRFXPHQWVDUHOLVWHGDFRPSDQ\¶VVXEPLWWHGEDVH-case 
,&(5RUUDQJHWKH(5*¶VSUHIHUUHG,&(5RUUDQJHWKHAC¶s preferred ICERs, as well as the committee¶s 
recommendations. On the whole, technologies are recommended for reimbursement if their ICER does not 
exceed the generally-accepted NICE threshold of £20,000-£30,000 per QALY[2, 5], although there is evidence 
that this threshold might sometimes be higher, even for technologies that do not satisfy criteria for end-of-life or 
EHLQJµKLJKO\-specialised¶[6, 7]. 
 
Changes to the NICE STA process have recently been proposed following consultation[8]. One of the proposals, 
and the focus of this paper, LV WKDW D QHZ µIDVW WUDFN¶ form of appraisal, a variant of the standard appraisal 
process, might be applied when a company submits a base-case ICER of less than £10,000 per QALY[8]. 
According to the consultation document, the stated intention behind the proposal appears to be twofold: to 
UHGXFHWKHWLPHIURPDWHFKQRORJ\¶VDSSURval by the European Medicines Agency to its being made available in 
the National Health Service (NHS) in England and Wales; and to reduce resource use by the companies and 
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NICE by conducting an abbreviated technology appraisal process (shorter, less extensive evidence review 
processes by ERGs and fewer AC meetings)[8]. It is worth noting that a second NICE consultation took place, 
which also SURSRVHG DQ µ$FFHOHUDWHG7HFKQRORJ\ $SSUDLVDO¶ SURFHVV 7KLV particular process was intended to 

IDVWWUDFN
WUHDWPHQWVWKDWZHUHµOLNHO\WRprovide similar or greater health benefits at a similar or lower cost than 
WHFKQRORJLHVDOUHDG\UHFRPPHQGHGLQWHFKQRORJ\DSSUDLVDOJXLGDQFHIRUWKHVDPHLQGLFDWLRQ¶.[9] Following the 
consultation this was integrated into the FTA process, but it is not the subject of this paper. 
 
This project was designed to explore how many STAs (2009-2016) had an original company base-case ICER of 
less than £10,000 per QALY and how many, after the full appraisal process, were recommended in the first ACD 
and in the FAD. It also assessed whether and by how much the ICER(s) preferred by the AC and stated in the 
ACD and in the FAD were different from the original company base-case ICER(s), especially if the ICER 
exceeded the generally-accepted NICE threshold of £20,000-£30,000 per QALY[2, 5]. This enabled an 
evidence-based assessment of the outcomes for previous STAs with company base-case ICERs of less than 
£10,000 per QALY. 
The research therefore aimed to answer the following questions:  
How many STAs had a company submitted base-case ICER of less than £10,000 per QALY, or the technology 
dominated its principal comparator?  
a. How many of these technologies received a positive recommendation in the ACD (or in the FAD, in 
those cases without an ACD)? 
b. How many of these technologies received a No or Minded No in the ACD? 
c. What reasons were given in the ACD for not recommending the technology?  
d. What was the final ICER and recommendation in the FAD?  
 
A secondary analysis was also conducted on STAs with an original company base-case ICER of between 
£10,000 and £15,000 per QALY to determine if outcomes were any different for this group. 
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Methods 
A content analysis was undertaken of documents relating to all STAs conducted by NICE between 2009 and 
December 2016 by members of research teams from the University of Sheffield and the University of Liverpool. 
This study focuses on 2009 onwards because the STA process, after four years of development, had become 
largely standardised by this point[10]. A first screen was conducted to identify those STAs with a company 
base-case ICER of less than £10,000 per QALY, as reported in the first ACD (or FAD if there was no ACD). 
More extensive data were then extracted into a standard form from the ACD and FAD documents relating to 
these STAs. The data to be extracted included: Technology Appraisal (TA) number; title of STA; date of FAD; 
name of company; ERG; disease area; company base-case ICERs; AC-preferred ICERs in the ACD; ACD 
recommendation (and details); AC-preferred ICERs in the FAD; and the FAD recommendation (and details).  
 
Data from the first 100 STAs with FADs had been collected for a previous project, which covered STAs from 
March 2009 to March 2014[3, 4, 6]. These data were extracted and checked by the two reviewers from the 
Sheffield team (CC, EK) and, in some instances, checked also by a member of the Liverpool team (RH). Where 
necessary, the original documents were all rechecked. The relevant documents of STAs from 1st April 2014 to 
December 2016 were publicly available on the NICE website and were checked and extracted by one member of 
the Liverpool team (RH) and double-checked by a second (AB). All ambiguous data were checked and 
discussed with all other members of the project team. The principal findings are summarised in a narrative and 
presented in tables, where relevant. Any instances where a technology was not recommended wholly in line 
with the original submission are discussed in detail, as are the issues that became apparent when examining 
these data. 
 
Results 
Between September 2009 and December 2016, there were 171 STAs for which final guidance had been 
published. These did not include STAs that had been withdrawn or for which the process had started but had 
been suspended. Nor did it include STAs in which the relevant ICERs were commercial-in-confidence (e.g.  
TA410), where all the necessary documents are not available online (e.g. TA368, TA372, TA376, TA396) or in 
which no company base-case ICER was reported (a cost minimisation analysis) (TA191). Such STAs were 
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therefore excluded from this analysis because the ICERs were absent or unusable. The final total was 171 STAs, 
for which final guidance had been published. Out of these 171 STAs, 117 were excluded because none of the 
company base-case ICERs reported in the ACD or FAD was £10,000 per QALY or less (or dominated the 
principal comparator(s)). However, five of these STAs had company base-case ICERs between £10,000 and 
£15,000 per QALY (TA216, TA275, TA345, TA355 and TA400). These were considered a potential group of 
interest, so are considered separately below. Out of the remaining 54 STAs, 28 had multiple company base-case 
ICERs for the principal indication (due to the provision of ICERs for different scenarios, comparisons and 
subgroups), one or more of which was less than £10,000 per QALY and one or more of which was more than 
£10,000 per QALY. These were excluded from the primary analysis because the\ZHUHXQOLNHO\WREHµIDVW-
WUDFNHG¶ given the presence of ICERs of more than £10,000 per QALY for certain relevant subgroups or 
comparisons. These STAs are also considered in more detail below. The total number of STAs with company 
base-case ICERs that all either dominated current treatments or were less than £10,000 per QALY in all 
comparisons was 26, which represents 15% (26/171) of all STAs with usable ICERs and published guidance. 
This is consistent with the 15% figure quoted by NICE[8]. Details of the selection process are provided in 
Figure X.  
 
<insert Figure: PRISMA flowchart of selection process> 
 
STAs with all company base-case ICERs of less than £10,000 per QALY or dominating comparators  
The technologies in 19 out of these 26 STAs (73%) received a positive recommendation after the first AC 
meeting. In 13 of these 19 STAs (68%) only a FAD was issued, there was no ACD (see Table 1). In eight of 
these 13 STAs (62%), the FRPSDQLHV¶ base-case ICERs (or conclusion on dominance), as recorded in the 
committee documents, remained the preferred ICER of the committee (including technologies with a Patient 
Access Scheme [PAS] in the case of TA305). In the five other instances, the AC-preferred ICER in the FAD 
was not explicitly stated (due to a PAS in the case of TA294) in three cases and was higher in two, but each 
technology was stated to be cost-effective.  For the six of the 19 technologies that generated positive 
recommendations, first in an ACD and then later, in the FAD, the AC-preferred ICER in the FAD was the same 
DVWKHFRPSDQ\¶VEDVH-FDVHLQRQH67$DQGKLJKHUWKDQWKHFRPSDQ\¶VEDVH-case in five STAs (but still below 
8 
 
£10,000 per QALY in four).  In one STA (TA335), the AC preferred ICER in the FAD, and its relationship to 
the company base-case ICER, was unclear. The details of these 19 STAs are presented in Table 1. 
 
<insert Table 1 here>  
 
Seven of the 26 STAs with all company base-case ICERs of less than £10,000 per QALY received a Minded No 
in the first ACD. All of these technologies ultimately received a positive recommendation in the FAD, but in 
some cases this recommendation was restricted by subgroup. The details of these seven STAs are presented in 
Table 2. In each case, the AC considered that the analyses provided by both the company and the ERG were 
inadequate for making a decision, and the AC could not identify a plausible ICER per QALY based on the 
evidence and model as presented.  
 
<insert Table 2 here> 
 
Four of the seven technologies were recommended fully in the FAD. However, it should be noted that, despite 
all four of these technologies originally dominating comparators or having company ICERs of less than £10,000 
per QALY, almost all of the final ICERs preferred by the AC and stated in the FADs fell between £10,000 and 
£30,000 per QALY, based on the additional analyses requested by the AC and conducted by the company or 
ERG. 
 
The remaining three of these seven STAs had more restrictive recommendations in the FAD. Two involved 
treatments for mental health conditions: aripiprazole for adolescent schizophrenia (TA213) and vortioxetine for 
major depressive episodes (TA367). In TA213 aripiprazole was originally indicated in the CS as a first-line 
therapy for the treatment of schizophrenia in adolescents (aged 15-17 years old) and the company base-case 
ICER was reported as £6,200 per QALY compared with olanzapine. However, the AC considered the principal 
comparator to be risperidone;  ERG analyses had reported much higher ICERs for this comparison. Given that 
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the final ICERs for aripiprazole as a first-line therapy were in excess of £30,000 per QALY, the final 
recommendation restricted its use to first-line only for patients who were intolerant to, or contraindicated for, 
the principal treatment, risperidone. In a similar way, the CS in TA367 had restricted vortioxetine to second-line 
treatment, but the FAD recommendation restricted reimbursement to third-line treatment, i.e. for patients who 
had had an inadequate response to two antidepressants within the current episode. Once more, the initial Minded 
No recommendation was due in part to the AC stating that relevant comparisons were absent from the CS. The 
third STA with restricted recommendations was for rituximab for ANCA-associated vasculitis (TA308).  The 
initial Minded No was because the AC was uncomfortable with uncertainties in the models submitted by the 
company and supplemented by the ERG, and therefore requested further analyses. As a result of these analyses, 
and contrary to the CS, the FAD only recommended rituximab for treatment-naïve patients in certain 
circumstances. 
 
Overall, the principal reasons for the Minded No recommendations in these seven STAs, despite their low 
ICERs, might be summarised as follows (a single submission might be affected by a number of issues) : 
implausible results or ICERs due to the models' failure to reflect clinical practice (TA229, TA261, TA367) or 
uncertainties in the model parameters or assumptions (TA213, TA260, TA261, TA308, TA367). The need for 
additional analyses was also precipitated by a failure of the models to take into account or use the comparisons 
(TA213, TA229, TA367) or outcomes (TA312) that the ACs deemed most relevant. 
 
STAs with company base-case ICERs of £10,000 to £15,000 per QALY  
Given that the proposed figure of £10,000 per QALY for 1,&(µfDVWWUDFN¶ consideration is not an absolute, we 
present here the evidence from five further STAs from our sample in which all of the company base-case ICERs 
were less than £15,000 per QALY. That is, if one of the FULWHULDIRUµIDVWWUDFN¶DSSUDLVDOZDVto be set at £15,000 
per QALY, then an additional five STAs become relevant to our analysis: thus, in total 31/171(18%) of 
previously completed STAs would be potentially eligible. These five additional STAs are summarised in Table 
3. 
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<insert Table 3 here> 
 
As with the majority of STAs with all company base-case ICERs of less than £10,000 per QALY that did not 
receive a Minded No in the ACD, all five of these STAs received a positive recommendation in the first AC 
meeting (and only a FAD was produced, there was no ACD). In three cases, the AC-preferred ICER in the FAD 
(the result of ERG analyses in each case) was higher than the original company base-case ICER, but all were 
below a cost-effectiveness threshold of £30,000 per QALY. Unlike the STAs considered in Table 1, this group 
includes two cancer technologies: bendamustine for chronic lymphocytic leukaemia (TA216) and nivolumab for 
advanced melanoma (TA400).  
 
STAs with company base-case ICERs ranging from less than £10,000 per QALY to more than £10,000 
per QALY 
In total 28/171 (16%) of all of the relevant STAs in this sample had one or more company base-case ICERs of 
less than £10,000 per QALY as well as one or more ICERS of more than £10,000 per QALY (see Table 
4).These were evenly spread across disease areas and ERGs, but it is noticeable that the last two years had more 
such STAs than the previous six years (15 for 2015-2016 compared with 13 for 2009-14). This perhaps reflects 
the increasing complexity of the assessments being conducted in the NICE STA process. 
 
<insert Table 4 here> 
 
It is no surprise that the picture for these 28 STAs is far more fragmentary than for those 26 STAs with all of the 
company base-ICERs below £10,000 per QALY. Only 39% (13/28) received an unrestricted, positive 
recommendation at the first AC. In seven of these, no ACD was produced at all, only a FAD, i.e. 25% (7/28) 
compared with 50% (13/26) in the group with company base-ICERs all below £15,000 per QALY. Further, 
technologies received a No or Minded No for all groups in 25% (7/28) of these STAs after the first AC and 
others were recommended in specific subgroups or circumstances only in 29% (8/28). All of the technologies in 
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these 28 STAs ultimately received a positive recommendation in the FAD, but in 32% (9/28) the 
recommendation was restricted to certain subgroups or lines of treatment and, in seven cases, was conditional on 
a PAS. In five of these seven cases, the PAS had been submitted along with the original company submission 
(see Table 4). 
 
Discussion 
Twenty-VL[67$VLQWKLVVDPSOHZRXOGKDYHVDWLVILHGWKHEDVLFFULWHULRQIRUWKHSURSRVHG1,&(µIDVWWUDFN¶
appraisal process, i.e. all of a company¶V submitted base-case ICERs for a technology and indication were less 
than £10,000 per QALY.. Following the example of previous STAs, this approach would make up to 18% of 
future STAs eligible for such a µIDVWWUDFN¶ process. Our analysis found that to73% (19/26) of these STAs 
received a straightforward, positive recommendation with an AC-preferred ICER in the FAD that fell below the 
£30,000 per QALY threshold of cost-effectiveness generally applied by NICE[2, 5]. 
 
However, the seven STAs with company base-case ICERs of less than £10,000 per QALY that received a 
Minded No in the ACD give particular pause for thought when considering the implications of these findings for 
WKHSURSRVHGµIDVWWUDFN¶process. In four of these STAs, the AC-preferred ICERs in the FAD, as a result of 
additional analyses performed by the company or the ERGs, had risen to almost £30,000 per QALY (still within 
existing thresholds of cost-effectiveness). Yet in the other three STAs (TA213, TA308 and TA367) the result 
was a recommendation restricted to certain subgroups or lines of treatment. In the case of TA213, the final 
preferred ICERs for the original proposal of first-line treatment were well in excess of the £30,000 per QALY 
threshold. The NHS could therefore have ended-up paying for a treatment for certain patients that might 
QRUPDOO\KDYHEHHQGHVLJQDWHGDV³QRWFRVW-HIIHFWLYH´, with the obvious implications and opportunity costs[5, 
11, 12]. It might be the case that the health system would be willing to fund non-cost-effective treatments for 
certain subgroups in return for providing more timely access to new treatments and a faster, less expensive 
technology appraisal process[8], although some might disagree[12].  
 
The NICE proposal has stated that criteria for inclusion in the µfast track¶ SURFHVVZRXOGEH³WKHDYDLODELOLW\RI
VWURQJHYLGHQFHZLWKDORZGHJUHHRIGHFLVLRQXQFHUWDLQW\´and that the ICER is indeed likely to be less than 
£10,000 per QALY. It was also anticipated that such technologies would EHLGHQWLILHGE\1,&(³IROORZLQJDQ
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DQDO\VLVRIWKHFRPSDQ\¶VVXEPLVVLRQVXSSRUWHGE\H[WHUQDOUHYLHZ´[8]. It is possible that STAs with issues, 
like the seven STAs with a company base-case ICER of less than £10,000 per QALY, and which received a 
Minded No in the ACD, might have been identified by this process DQG³UH-URXWHG´WRWKHVWDQGDUG67$SURFHVV
After all, the CS and models in four of these seven STAs were potentially easily identifiable as having a high 
degree of decision uncertainty on account of their failure to provide comparisons against the most relevant 
current treatments (TA213, TA229, TA367) and/or their failure to reflect UK clinical practice (TA229, TA261, 
TA367). However, it is questionable whether a more limited appraisal process might have identified the 
uncertainties in the model parameters and assumptions that affected five of these STAs (TA213, TA260, 
TA261, TA308, TA367). Indeed, the current SURFHVV¶Vheavy reliance on the ERGs to identify such issues is 
well known[3]. 
 
Based on the evidence, the group of 26 STAs with ICERs all less than £10,000 per QALY, and the group of five 
STAs with ICERs between £10,000 and £15,000 per QALY, all do appear to represent a generally quite 
homogenous type of STA. Only 13 of these 31 STAs had multiple ICERs and, of course, the range was very 
narrow (from the new technology dominating comparators to always being less than £15,000 per QALY). This 
means that 18 of these 31 STAs (58%) had only a single company base-case ICER. The groups and scenarios 
within these appraisals were fairly homogenous and thus required less complex methodology than other STAs. 
This accords with the NICE FRQVXOWDWLRQSURSRVDOWKDW³WKHZHLJKWDQGFRPSOH[LW\´RIWKHappraisals should be 
³in proportion to the technical challenges and the risks posed by the evidence that it considers´[8]. And thus, 
the µIDVWWUDFN¶DSSUDLVDOSURFHVV was only to be for ³the appraisal of health technologies for which a confident 
judgement about value for money can be made at an early stage´[8]. However, such a judgement could not 
possibly be made, for example, for the 28 STAs with company base-case ICERs both less than and more than 
£10,000 per QALY, in which companies submitted multiple base-case ICERs for their technology, which might 
range from dominating to being dominated by comparators (e.g. TA349) on account of different subgroups, 
treatment lines or scenarios. Such technologies must be appraised via the standard process. 
 
Another scenario arises when a relevant comparator product already has a confidential PAS in place with the 
Department of Health.  In this case, an ERG is required to generate results taking into account all of the PAS 
discounts.  In our dataset, two of the STAs (TA346 and TA366) with company base-case ICERs all less than 
£10,000 were subject to this additional process, as were two STAs (TA384 and TA415) within the group 
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containing multiple ICERs, some of which were below £10,000.  This information can be identified at the outset 
and would allow some technologies to be quickly categorised as not being eligible for the µfast track¶ process, if 
the presence of such an issue was deemed to require more work. 
 
One particular pattern is noticeable in the 19 STAs with all ICERs less than £10,000 per QALY and with 
µVWUDLJKWIRUZDUG¶SRVLWLYHUHFRPPHQGDWLRQV. Six of the 19 (32%) comprise treatments for cardiovascular disease 
and four (21%) relate to treatments for eyes. We consider that these disease areas are disproportionately highly 
represented in this group. In a study of the first 100 STAs with published guidance (2009-2014), frequencies 
were 11% for cardiovascular disease therapies and 7% for eye therapies and treatments for cancer, for blood and 
immune system and musculoskeletal conditions, frequencies were all higher than 7% [4, 6, 10]. In our dataset, 
WKUHHRIWKHIRXU³H\H´67$VHYDOXDWHGDIOLEHUFHSWIRUGLIIHUHQWLQGLFDWLRQVDQGWKLVGUXJKDVDUHODWLYHO\ORZ-
intensity regimen (with relatively low associated costs) compared with currently licensed comparators[13], for 
H[DPSOHUDQLEL]XPDEZKLFKZDVWKHVXEMHFWRIWKHIRXUWK³H\H´67$7KHUHODWLYHO\KLJKHUSURSRUWLRQVRI
cardiovascular and eye treatments in this sample of STAs might also be due in part to the lower costs of 
treatments for these particular disease areas relative to others, such as cancer or musculoskeletal conditions[14, 
15]. There did not appear to be any particularly noticeable increase in these STAs over time (see Tables 1 and 
2): there were the same number of STAs (n=4) with a company base-case ICER of less than £10,000 per QALY 
in 2011, 2012 and 2013, and only slight increases in 2014 (n=6) and 2015 (n=5). However, this might change in 
the future. 
 
In 74% (23/31) of STAs with technologies with company base-case ICERs all below £15,000 per QALY, this 
represented the first time the technology was being assessed by NICE (for any indication). These cases therefore 
all potentially represented cost precedents for future submissions, even for different indications. In five of the 
remaining eight STAs (TA264, TA275, TA292, TA327, TA335), the technologies had received prior 
recommendations for essentially the same indication, either as long as five years before the relevant appraisal, 
e.g. alteplase for acute ischaemic stroke in 2007 (TA122) and 2012 (TA264), or as little as one year before the 
relevant appraisal, e.g. apixaban for embolisms in 2012 (TA245) and 2013 (TA275). In only three cases were 
there prior appraisals of the same technology for different indications: bendamustine for chronic lymphocytic 
leukaemia: TA216 (2011) had been preceded by bendamustine for non-+RGJNLQ¶VO\PSKRPD7$
rituximab for treating anti-neutrophil cytoplasmic antibody-associated vasculitis: TA308 (2014) had been 
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preceded by technology appraisals for a number of lymphoma indications and rheumatoid arthritis between 
2002 (TA37) and 2009 (TA174); and finally ranibizumab for treating choroidal neovascularisation associated 
with pathological myopia: TA298 (2013) had been the subject of previous appraisals between 2008 and 2011 for 
macular degeneration and macular oedema (TA 155, TA229, TA237). 
 
The strength of this research is that it represents an analysis of all NICE STAs with published final guidance 
from September 2009 to December 2016, and thus offers an excellent summary of current and recent practice.  
The double-checking of all key data across the 171 included STAs, by at least two experienced HTA researchers 
from two research teams (Sheffield and Liverpool), reduced the likelihood of inconsistency and inaccuracy in 
the data.  In addition, the method of analysis was descriptive, which reduces the likelihood of overstating 
relationships in the data, and an inclusive approach was taken to managing data that were not straightforward, 
for example the presence of multiple ICERs.  
 
There are however limitations to this study.  There are inherent weaknesses in using documentary analysis in 
that the researcher is only able to analyse what has been reported.  The level and type of detail provided in and 
across the ACDs and FADs could be very different, which made data extraction at times a matter of 
interpretation. The so-called original company base-case ICERs, as reported in the ACD or FAD, are possibly 
likely to be different in an unknown number of instances from the ICERs submitted by companies at the very 
start of the process because, as a minimum, they will have been subject to the clarification process led by the 
ERG[1], and so could have already been revised before the first AC meeting DQGWKDWFRPPLWWHH¶Vrequest for 
any revisions or additional analyses. It is also unclear exactly how a new µIDVW WUDFN¶process might be 
operationalised, so assumptions have had to be made in this study and it is not possible to know exactly how far 
such a process might or might not identify STAs with issues requiring more extensive work. Finally, it is not 
possible WRGHWHUPLQHIURPWKHFXUUHQWVWXG\DQGDQDO\VLVZKHWKHUWKHSURSRVHGµIDVWWUDFN¶SURFHVVZLOOEH
adequate to identify all of the issues that might arise with a submission that has a company base-case ICER of 
less than £10,000 per QALY or how far the existence of this criterion might influence submissions; this study 
only explored what had happened with previous STAs that satisfied this basic criterion. These limitations 
suggest that caution should be exercised regarding some of the conclusions drawn from the evidence.   
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Conclusion 
The majority of previous STAs with a company base-case ICER of £10,000 or even £15,000 per QALY 
received a positive recommendation after the first AC, but a number proved more complicated and required 
detailed appraisal, which influenced the final recommendation. In 19 of the 26 STAs that satisfy the £10,000 per 
QALY threshold in this sample, the technologies received a positive recommendation after the first AC meeting 
with little or no amendment to the original company base-case ICERs in the FAD. The same finding applied to 
another group of five STAs with company base-case ICERs below £15,000 per QALY. However, in seven of 
the STAs with all company base-case ICERs below £10,000 per QALY, the technology received an initial 
Minded No and, in three cases (43%), the indicated patient groups were more restricted in the final 
UHFRPPHQGDWLRQWKDQLQWKHFRPSDQLHV¶RULJLQDOVXEPLVVLRQV$GGLWLRQDODQDO\VHVand work by the companies 
and ERGs had demonstrated that the relevant base-case ICERs might actually be much higher and the 
technologies might not be cost-HIIHFWLYHIRUFHUWDLQSDWLHQWJURXSV,WLVXQFHUWDLQZKHWKHUDµIDVWWUDFN¶SURFHVV
would have identified these issues.
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Table 1: Summary of STAs with company base-case ICERs <£10,000 per QALY that received a positive recommendation at first time of asking 
TA 
number 
FAD date Technology Disease area ERG ACD, 
FAD 
FAD-preferred ICER Relative to original 
ICER 
230 2011 Bivalirudin Cardiovascular ScHARR FAD Dominates Same* 
236 2011 Ticagrelor Cardiovascular LRiG ACD, FAD <£10,000 Higher 
264 2012 Alteplase Cardiovascular ScHARR FAD <£10,000 Same 
267 2012 Ivabradine Cardiovascular BMJ Evidence ACD, FAD <£10,000 Same 
290 2013 Mirabegron Urogenital BMJ Evidence ACD, FAD <£10,000 Higher 
292 2013 Aripiprazole Mental health  ScHARR FAD Dominates Unclear 
294 2013 Aflibercept Eye Aberdeen FAD Dominates (with PAS) Same 
298 2013 Ranibizumab Eye Aberdeen FAD Dominates Same 
305 2014 Aflibercept Eye Warwick  FAD <£10,000 and dominates (with PAS) Same 
318 2014 Lubiprostone Digestive system CRD York FAD Dominates Same 
325 2014 Nalmefene Alcohol dependence ScHARR ACD, FAD <£10,000 Higher 
327 2014 Dabigatran 
etexilate 
Cardiovascular BMJ FAD Unclear but within acceptable range Higher 
335 2015 Rivaroxaban Cardiovascular ScHARR ACD, FAD Unclear but within acceptable range Unclear 
346 2015 Aflibercept Eye Aberdeen ACD, FAD Unclear but within acceptable range 
ZLWK3$6Á 
Higher 
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TA 
number 
FAD date Technology Disease area ERG ACD, 
FAD 
FAD-preferred ICER Relative to original 
ICER 
350 2015 Secukinumab Psoriasis Aberdeen FAD Unclear but within acceptable range 
(with PAS) 
Unclear 
366 2015 Pembrolizumab Cancer LRiG FAD Unclear but within acceptable range 
ZLWK3$6Á 
Unclear 
407 2016 Secukinumab Musculoskeletal Kleijnen SR FAD <£10,000 (with PAS) Same 
408 2016 Pegaspargase Blood & Immune Kleijnen SR FAD Dominates Same 
418 2016 Dapagliflozin Diabetes Warwick FAD Unclear but within acceptable range Higher 
*Different figures, but still dominates.  PAS: Patient Access Scheme. A specific final ICER was confidential or not reported. Á,QFOXGHV3$6IRUFRPSDUDWRUV 
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Table 2: Summary of STAs with company base-case ICERs <£10,000 per QALY that received an initial Minded No recommendation in the ACD 
TA 
number 
FAD 
date 
Technology Disease 
area 
ERG ACD reason for decision FAD decision FAD ICER (source) 
213 2011 Aripiprazole Mental 
Health 
Southampton 4.7, 4.12: The AC requested more evidence on 
comparisons other than olanzapine, especially 
for risperidone, the principal, routinely-used 
comparator in UK clinical practice. 
4.14: The AC was concerned that, due to a 
number of uncertainties in the model, the ICER 
could be as high as £233,000 per QALY gained 
(in line with sensitivity analyses conducted by 
the ERG) and that aripiprazole was dominated 
by risperidone in the ERG's exploratory analyses 
1.1: Recommended only in a 
subgroup of the original 
indication (people aged 15 to 17 
years who are intolerant of 
risperidone, or for whom 
risperidone is contraindicated, or 
whose schizophrenia has not been 
adequately controlled with 
risperidone) 
4.12: As first line, the 
ICERs ranged from 
£52,750 to £108,800 when 
compared with treatment 
sequences in 
which risperidone is used 
first FRPSDQ\¶VXSGDWHG
base-case analysis) 
229 2011 Dexametha-
sone implants 
Eye Aberdeen 4.35: Submission did not compare the new 
technology with any of the active comparators 
listed in the scope and identified by the ERG 
DORQJDQGRWKHUVWDNHKROGHUV«&RVWRI
treatment and extrapolations beyond data from 
the trial "were not plausible and did not reflect 
FOLQLFDOSUDFWLFHLQWKH8.«7KH&RPPLWWHH
were therefore unable to estimate the most 
plausible ICER 
1.1: Recommended 4.20FRPSDQ\¶V
updated base-case analysis) 
260 2012 Botulinum 
toxin type A 
Chronic 
migraine 
Warwick 4.19: On the basis of the evidence submitted to 
the AC, it was unable to conclude whether 
botulinum toxin type A was cost effective 
compared to standard care. The central estimate 
of probabilistic ICER was not presented and 
there was uncertainty in many of the modelled 
parameters. 
1.1: Recommended 4.15: £18,900  (ERG 
DQDO\VLVRIFRPSDQ\¶V
updated base-case analysis) 
261 2012 Rivaroxaban Blood & 
Immune 
ScHARR 1.2, 4.13, 4.15, 4.16: The main limitation of the 
PRGHOIURPWKH$&¶VSRLQWRIYLHZZDVWKDW
patients were only treated with the drug for 12 
months yet in practice people may need ongoing 
anticoagulation. The AC also considered the 
assessment of cost-effectiveness in different 
subgroups to be uncertain and therefore 
requested further evidence to support the 
assumptions. 
1.1: Recommended 4.13, 4.16: Most likely 
ICERs based on length of 
treatment duration ranged 
from dominating 
comparators (3 months) to 
£19,400 per QALY for 
people who need treatment 
beyond 12 months (ERG 
analysis)  
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TA 
number 
FAD 
date 
Technology Disease 
area 
ERG ACD reason for decision FAD decision FAD ICER (source) 
308 2014 Rituximab Blood & 
Immune  
ScHARR 4.17: The AC concluded that none of the ICERs 
presented by the manufacturer and the ERG 
provided an accurate cost-effectiveness estimate 
due to uncertainties pertaining to model 
parameters, such as unrealistic outpatient costs 
and utility values and incomplete and 
inappropriate treatment sequences. Additional 
analyses were needed. 
1.1: Recommended only if: 
further cyclophosphamide 
treatment would exceed the 
maximum cumulative 
cyclophosphamide dose; or 
cyclophosphamide is 
contraindicated or not tolerated; 
or the person has not completed 
their family and treatment with 
cyclophosphamide may 
materially affect their fertility; or 
the disease has remained active or 
progressed despite a course of 
cyclophosphamide lasting 3±6 
months; or the person has had 
uroepithelial malignancy 
4.18: £12,100 for people 
who can have 
cyclophosphamide, less 
than £30,000 for those who 
cannot (ERG analysis) 
312 2014 Alemtuzumab Central 
Nervous 
System 
Southampton 4.10, 4.11: The AC concluded that the primary 
outcome measure for the MTC should be 
sustained accumulation of disability lasting 6 
months because this was a co-primary outcome 
in the clinical trials. 
The number of QALYs accumulated over the 
lifetime of the model was deemed to be 
implausibly low. 
1.1: Recommended 4.21: ICER considered to 
be between £13,600 and 
£24,500 compared to 
glatiramer acetate and 
(4.22) £8,900 compared to 
fingolimod for a different 
population FRPSDQ\¶V
updated base-case analysis) 
367 2015 Vortioxetine Mental 
Health 
York CRD 1.2, 4.12, 4.20: The only population modelled 
was for second-line treatment; AC was 
interested in other comparisons / lines. 4.12, 
4.13, 4.16: AC thought the model structure 
lacked validity and that the resource use and 
costs did not reflect the pathway of care for the 
indicated population. 
1.1:  Recommended only in 
people who have had an 
inadequate response to two 
antidepressants within the current 
episode (3rd line) 
4.12: All scenario ICERs 
against all comparators 
were less than £9,000 when 
equal efficacy between 
treatments is assumed 
FRPSDQ\¶VXSGDWHGEDVH-
case analysis) 
ACD: Appraisal Consultation Documents; FAD: Final Appraisal Determination; ICER: Incremental Cost-Effectiveness Ratio; AC: Appraisal Committee; MTC: Mixed 
Treatment Comparison 
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Table 3: Summary of STAs with company base-case ICERs £10,000 to £15,000 per QALY  
TA 
number 
FAD date Technology Disease area ERG ACD, FAD FAD-preferred ICER Relative to original ICER 
216 2011 Bendamustine Cancer PENTAG FAD <£10,000 Lower (£12,000) 
275 2013 Apixaban Cardiovascular BMJ Evidence FAD <£20,000 Higher 
345 2015 Naloxegol Digestive system Kleijnen SR FAD <£13,000 Same 
355 2015 Edoxaban Cardiovascular LRiG FAD <£16,000 Higher 
400 2016 Nivolumab Cancer BMJ Evidence FAD <£30,000* (with PAS) Higher 
*As long as combination technology is costed according to its Patient Access Scheme PAS). 
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Table 4: Summary of STAs with company base-case ICERs ranging from less than to more than £10,000 per QALY  
TA 
number 
FAD date Technology Disease area ERG ACD decision FAD decision 
182 2009 Prasugrel Cardiovascular LRiG Recommended Recommended 
186 2010 Certolizumab pegol Musculoskeletal West 
Midlands 
Minded No Recommended (with PAS*) 
197 2010 Dronedarone Cardiovascular York CRD Not recommended Recommended for second line only 
203 2010 Liraglutide Blood & Immune Aberdeen Restricted recommendations Recommended (in certain subgroups) 
248 2012 Exenatide Blood & Immune Warwick Recommended Recommended 
249 2012 Dabigatran etexilate Cardiovascular York CRD Minded No Recommended 
252 2012 Telaprevir Hepatitis Southampton No ACD Recommended 
253 2012 Boceprevir Hepatitis Southampton No ACD Recommended 
287 2013 Rivaroxaban Blood & Immune Southampton No ACD Recommended 
293 2013 Eltrombopag Blood & Immune Aberdeen Recommended Recommended 
315 2014 Canagliflozin Endocrine Southampton Restricted recommendations Recommended (in certain subgroups) 
317 2014 Prasugrel Cardiovascular LRiG Recommended Recommended 
326 2014 Imatinib Cancer Southampton Recommended Recommended 
330 2015 Sofosbuvir Hepatitis Southampton Minded No Recommended 
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TA 
number 
FAD date Technology Disease area ERG ACD decision FAD decision 
331 2015 Simeprevir Hepatitis Southampton Restricted recommendations Recommended 
336 2015 Empagliflozin Endocrine Warwick  Minded No Recommended (in certain subgroups) 
341 2015 Apixaban Cardiovascular LRiG No ACD Recommended 
342 2015 Vedolizumab Digestive system ScHARR Restricted recommendations Recommended (with PAS*) 
349 2015 Dexamethasone 
LPSODQWVÁ 
Eyes BMJ Evidence Restricted recommendations Recommended (in certain subgroups) 
354 2015 Edoxaban Cardiovascular BMJ Evidence No ACD Recommended 
359 2015 Idelalisib Cancer Warwick Minded No and No Recommended (in certain subgroups) (with 
PAS*) 
363 2015 Ledipasvir / sofosbuvir Hepatitis ScHARR Restricted recommendations Recommended (in certain subgroups) (with 
PAS) 
364 2015 Daclatasvir Hepatitis York CRD Restricted recommendations Recommended (in certain subgroups) (with 
PAS) 
365 2015 Ombitasvir / 
paritaprevir / ritonavir 
+/- dasabuvir 
Hepatitis Southampton Recommended Recommended 
384 2016 1LYROXPDEÁ Cancer Southampton No ACD Recommended 
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TA 
number 
FAD date Technology Disease area ERG ACD decision FAD decision 
413 2016 Elbasvir±grazoprevir Hepatitis Kleijnen SR No ACD Recommended (with PAS*) 
415 2016 Certolizumab pegol Musculoskeletal ScHARR Restricted recommendations Recommended (in certain subgroups) (with 
PAS*) 
424 2016 Pertuzumab Cancer ScHARR Not recommended Recommended 
Á,QFOXGHV3$6IRUFRPSDUDWRUV *PAS submitted with original company submission. 
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Appendix: STAs cited within the manuscript  
All documents are available from the NICE website: https://www.nice.org.uk/  
NICE TA 
number 
Full Appraisal Title 
TA182 Prasugrel for the treatment of acute coronary syndromes with percutaneous 
coronary intervention 
TA186 Certolizumab pegol for the treatment of rheumatoid arthritis 
TA189 Sorafenib for the treatment of advanced hepatocellular carcinoma 
TA191 Capecitabine for the treatment of advanced gastric cancer 
TA197 Dronedarone for the treatment of non-permanent atrial fibrillation 
TA203 Liraglutide for the treatment of type 2 diabetes mellitus 
TA213 Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years 
TA216 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia 
TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary 
to retinal vein occlusion 
TA230 Bivalirudin for the treatment of ST-segment-elevation myocardial infarction 
TA236 Ticagrelor for the treatment of acute coronary syndromes 
TA248 Exenatide prolonged-release suspension for injection in combination with oral 
antidiabetic therapy for the treatment of type 2 diabetes 
TA249 Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial 
fibrillation 
TA252 Telaprevir for the treatment of genotype 1 chronic hepatitis C 
TA253 Boceprevir for the treatment of genotype 1 chronic hepatitis C 
TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic 
migraine 
TA261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent 
deep vein thrombosis and pulmonary embolism 
TA264 Alteplase for treating acute ischaemic stroke 
TA267 Ivabradine for treating chronic heart failure 
TA275 Apixaban for preventing stroke and systemic embolism in people with nonvalvular 
atrial fibrillation 
TA287 Bevacizumab in combination with gemcitabine and carboplatin for treating the first 
recurrence of platinum-sensitive advanced ovarian cancer 
TA290 Mirabegron for treating symptoms of overactive bladder 
TA292 Aripiprazole for treating moderate to severe manic episodes in adolescents with 
bipolar I disorder 
TA293 Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura 
TA294 Aflibercept solution for injection for treating wet age̻related macular degeneration 
TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological 
myopia 
TA305 Aflibercept for treating visual impairment caused by macular oedema secondary to 
central retinal vein occlusion 
TA308 Rituximab in combination with glucocorticoids for treating anti-neutrophil 
cytoplasmic antibody-associated vasculitis 
TA312 Alemtuzumab for treating relapsing̻remitting multiple sclerosis 
TA315 Canagliflozin in combination therapy for treating type 2 diabetes 
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TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary 
syndromes 
TA318 Lubiprostone for treating chronic idiopathic constipation 
TA325 Nalmefene for reducing alcohol consumption in people with alcohol dependence 
TA326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours 
TA327 Dabigatran etexilate for the treatment and secondary prevention of deep vein 
thrombosis and/or pulmonary embolism 
TA330 Sofosbuvir for treating chronic hepatitis C 
TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute 
coronary 
TA336 Empagliflozin in combination therapy for treating type 2 diabetes 
TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis 
and/or pulmonary embolism 
TA342 Vedolizumab for treating moderately to severely active ulcerative colitis 
TA345 Naloxegol for treating opioidǦinduced constipation 
TA346 Aflibercept for treating diabetic macular oedema 
TA349 Dexamethasone intravitreal implant for treating diabetic macular oedema 
TA350 Secukinumab for treating moderate to severe plaque psoriasis 
TA354 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary 
embolism 
TA355 Edoxaban for preventing stroke and systemic embolism in people with non-
valvular atrial fibrillation 
TA359 Idelalisib for treating chronic lymphocytic leukaemia 
TA363 Ledipasvir±sofosbuvir for treating chronic hepatitis C 
TA364 Daclatasvir for treating chronic hepatitis C 
TA365  Ombitasvir±paritaprevir±ritonavir with or without dasabuvir for treating chronic 
hepatitis C 
TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab 
TA367 Vortioxetine for treating major depressive episodes 
TA368 Apremilast for treating moderate to severe plaque psoriasis 
TA372 Apremilast for treating active psoriatic arthritis 
TA376 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone 
metastases 
TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma 
TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic 
melanoma 
TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma 
TA407 Secukinumab for active ankylosing spondylitis after treatment with non-steroidal 
anti-inflammatory drugs or TNF-alpha inhibitors 
TA408 Pegaspargase for treating acute lymphoblastic leukaemia 
TA410 Talimogene laherparepvec for treating unresectable metastatic melanoma 
TA413 Elbasvir±grazoprevir for treating chronic hepatitis C 
TA415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a 
TNF-alpha inhibitor 
TA418 Dapagliflozin in triple therapy for treating type 2 diabetes 
TA424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer  
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: PRISMA flowchart of STA selection process 
 
 
 
STAs 
n=171 
117 STAs with company 
base-case ICERs all 
>£10K per QALY  
(5/117 STAs with 
company base-case ICERs 
29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
